Differential penetration of raltegravir throughout gastrointestinal tissue

Single- and Multiple-Dose Pharmacokinetics of Darunavir Plus Ritonavir and Etravirine in Semen and Rectal Tissue of HIV-Negative Men

(2012) Kevin C. Brown et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

A novel ultrasensitive LC–MS/MS assay for quantification of intracellular raltegravir in human cell extracts

(2012) Brian L. Robbins et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

(2012) N. M. Archin et al.   NATURE

Shock and kill

(2012) Steven G. Deeks   NATURE

Impact of Multi-Targeted Antiretroviral Treatment on Gut T Cell Depletion and HIV Reservoir Seeding during Acute HIV Infection

(2012) Jintanat Ananworanich et al.   PLoS One

A Highly Intensified ART Regimen Induces Long-Term Viral Suppression and Restriction of the Viral Reservoir in a Simian AIDS Model

(2012) Iart Luca Shytaj et al.   PLoS Pathogens

A Randomized, Controlled Trial of Raltegravir Intensification in Antiretroviral-treated, HIV-infected Patients with a Suboptimal CD4+ T Cell Response

(2011) Hiroyu Hatano et al.   JOURNAL OF INFECTIOUS DISEASES

Single and Multiple Dose Pharmacokinetics of Maraviroc in Saliva, Semen, and Rectal Tissue of Healthy HIV-Negative Men

(2011) Kevin C. Brown et al.   JOURNAL OF INFECTIOUS DISEASES

Disulfiram Reactivates Latent HIV-1 in a Bcl-2-Transduced Primary CD4+ T Cell Model without Inducing Global T Cell Activation

(2011) S. Xing et al.   JOURNAL OF VIROLOGY

Tissue Says Blood Is Misleading, Confusing HIV Cure Efforts

(2011) J. Cohen   SCIENCE

Penetration of Tenofovir and Emtricitabine in Mucosal Tissues: Implications for Prevention of HIV-1 Transmission

(2011) K. B. Patterson et al.   Science Translational Medicine

Short‐Course Raltegravir Intensification Does Not Reduce Persistent Low‐Level Viremia in Patients with HIV‐1 Suppression during Receipt of Combination Antiretroviral Therapy

(2010) D. McMahon et al.   CLINICAL INFECTIOUS DISEASES

Pharmacologic Opportunities for HIV Prevention

(2010) M R Nicol et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Differences in HIV Burden and Immune Activation within the Gut of HIV‐Positive Patients Receiving Suppressive Antiretroviral Therapy

(2010) Steven A. Yukl et al.   JOURNAL OF INFECTIOUS DISEASES

Antiretroviral Intensification and Valproic Acid Lack Sustained Effect on Residual HIV-1 Viremia or Resting CD4+ Cell Infection

(2010) Nancie M. Archin et al.   PLoS One

The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial

(2010) Rajesh T. Gandhi et al.   PLOS MEDICINE

Maraviroc Concentrates in the Cervicovaginal Fluid and Vaginal Tissue of HIV-Negative Women

(2009) Julie B Dumond et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy

(2009) J. B. Dinoso et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells

(2008) Nancy M Archin et al.   AIDS

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

(2008)   LANCET

HIV Integrase Inhibitors — Out of the Pipeline and into the Clinic

(2008) Diane V. Havlir   NEW ENGLAND JOURNAL OF MEDICINE

HIV rebounds from latently infected cells, rather than from continuing low-level replication

(2008) B. Joos et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA